Drug Oncology

Pluvicto

Payments companies reported to CMS as associated with Pluvicto. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.6Massociated payments (2023-2025)
11,821clinicians with associated payments
4companies reporting

By year

2023 $348K
2024 $419K
2025 $840K

Payments reported as associated with Pluvicto, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Hematology & Oncology $455K
Urology $383K
Radiation Oncology $176K
Medical Oncology $168K
Family $98K
Nurse Practitioner $58K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Pluvicto

These are the largest totals companies reported as associated with Pluvicto. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Luke Nordquist Omaha, NE Hematology & Oncology $163,928.02
Neal Shore Myrtle Beach, SC Urology $52,825.75
Alton Sartor Rochester, MN Medical Oncology $29,640.33
Jason Hafron West Bloomfield, MI Urology $28,489.73
Bryan Mehlhaff Springfield, OR Urology $24,706.48
Gordon Brown Cherry Hill, NJ Urology $22,721.07
Shawn Zimberg Plainview, NY Radiation Oncology $19,542.48
Daniel George Durham, NC Urology $17,971.30
Steven Finkelstein Syracuse, NY Radiation Oncology $17,645.36
Ulka Vaishampayan Ann Arbor, MI Internal Medicine $17,519.44

Prescribed Pluvicto?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.